The importance of the use of an inhibitor with large selectivity for HDAC6 such as C11 is that it can overcome all of the neuronal toxicity associated with the use of pan-HDAC inhibitors, suggesting that its specific inhibition may eliminate a range of untoward effects seen with the clinical application of pan-HDAC inhibitors in cancer [69]. The gene discussed is HDAC9; the disease is cancer.